Literature DB >> 21371998

Development of a sensitive ELISA to quantify apolipoprotein CIII in nonhuman primate serum.

Yuxin Wang1, Zhili Song, Janice D Wagner, Catherine Pachuk, Romesh R Subramanian.   

Abstract

Apolipoprotein CIII (apoCIII), a major constituent of triglyceride-rich lipoprotein, has been proposed as a key contributor to hypertriglyceridemia on the basis of its inhibitory effects on lipoprotein lipase. Many immunochemical methods have been developed for human apoCIII quantification, including ELISA. However, a sensitive and quantitative assay for nonhuman primates is not commercially available. We developed a sensitive, quantitative, and highly specific sandwich ELISA to measure apoCIII in both nonhuman primate and human serum. Our assay generates a linear calibration curve from 0.01 μg/ml to 10 μg/ml using an apoCIII standard that was purified from cynomolgus monkey serum. It is highly reproducible (intra- and interplate CV < 5% and < 8%, respectively), sensitive enough to distinguish 10% difference of apoCIII present in serum, and has no interference from purified human apolipoprotein AI, AII, B, CI, CII, or E. The same assay can also be used to measure human apoCIII with a linear calibration curve from 0.005 μg/ml to 1 μg/ml using purified human apoCIII as the standard. This fast and highly sensitive ELISA could be a useful tool to investigate the role of apoCIII in lipoprotein transport and cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21371998      PMCID: PMC3090247          DOI: 10.1194/jlr.D011148

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  18 in total

1.  Immunochemical methods for quantification of human apolipoprotein C-III.

Authors:  M L Kashyap
Journal:  Methods Enzymol       Date:  1996       Impact factor: 1.600

2.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

3.  Isolation and properties of human apolipoproteins C-I, C-II, and C-III.

Authors:  R L Jackson; G Holdsworth
Journal:  Methods Enzymol       Date:  1986       Impact factor: 1.600

4.  Enzyme linked immunosorbent assay for human apolipoprotein C-III.

Authors:  J Bury; M Rosseneu
Journal:  J Clin Chem Clin Biochem       Date:  1985-02

5.  Effects of fenofibrate on lipid parameters in obese rhesus monkeys.

Authors:  D A Winegar; P J Brown; W O Wilkison; M C Lewis; R J Ott; W Q Tong; H R Brown; J M Lehmann; S A Kliewer; K D Plunket; J M Way; N L Bodkin; B C Hansen
Journal:  J Lipid Res       Date:  2001-10       Impact factor: 5.922

6.  A selective peroxisome proliferator-activated receptor alpha agonist, CP-900691, improves plasma lipids, lipoproteins, and glycemic control in diabetic monkeys.

Authors:  Janice D Wagner; Melanie K Shadoan; Li Zhang; Gina M Ward; Lori J Royer; Kylie Kavanagh; Omar L Francone; Bruce J Auerbach; H James Harwood
Journal:  J Pharmacol Exp Ther       Date:  2010-02-26       Impact factor: 4.030

7.  Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice.

Authors:  Y Ito; N Azrolan; A O'Connell; A Walsh; J L Breslow
Journal:  Science       Date:  1990-08-17       Impact factor: 47.728

8.  Homologues of the human C and A apolipoproteins in the Macaca fascicularis (cynomolgus) monkey.

Authors:  P N Herbert; L L Bausserman; K M Lynch; A L Saritelli; M A Kantor; R J Nicolosi; R S Shulman
Journal:  Biochemistry       Date:  1987-03-10       Impact factor: 3.162

9.  Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia.

Authors:  N Maeda; H Li; D Lee; P Oliver; S H Quarfordt; J Osada
Journal:  J Biol Chem       Date:  1994-09-23       Impact factor: 5.157

10.  Nucleotide sequences of the Macaca fascicularis apolipoprotein C-III and A-IV genes.

Authors:  J Osada; M Pocoví; R J Nicolosi; E J Schaefer; J M Ordovás
Journal:  Biochim Biophys Acta       Date:  1993-03-20
View more
  2 in total

1.  Targeting Neph1 and ZO-1 protein-protein interaction in podocytes prevents podocyte injury and preserves glomerular filtration function.

Authors:  Amin Sagar; Ehtesham Arif; Ashish Kumar Solanki; Pankaj Srivastava; Michael G Janech; Seok-Hyung Kim; Joshua H Lipschutz; Sang-Ho Kwon; Deepak Nihalani
Journal:  Sci Rep       Date:  2017-09-21       Impact factor: 4.379

Review 2.  Why Is Apolipoprotein CIII Emerging as a Novel Therapeutic Target to Reduce the Burden of Cardiovascular Disease?

Authors:  Marja-Riitta Taskinen; Jan Borén
Journal:  Curr Atheroscler Rep       Date:  2016-10       Impact factor: 5.113

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.